Tacrolimus and mycophenolate mofetil are immunosuppressants frequently used in human organ transplantation. Tacrolimus is also reported to inhibit Plasmodium falciparum growth in vitro. Here, we report that tacrolimus prevented the death from cerebral malaria of Plasmodium berghei ANKA-infected C57BL/6J mice, but not their death from malaria due to the high parasitaemia and severe anaemia. The mycophenolate mofetiltreated mice showed higher mortality from cerebral malaria and succumbed to malaria earlier than tacrolimus-treated littermates. Tacrolimus attenuated the infiltration of mononuclear cells including pathogenic CD8 + T cells into the brain. It appears to prevent murine cerebral malaria through the inhibition of cerebral infiltration of CD8 + T cells.
Introduction
Cerebral malaria (CM) is a lethal complication of Plasmodium falciparum infection and is associated with a 10-20% mortality rate in Africa. 1, 2 Long-term neurological and cognitive deficits or epilepsy present in 25-50% of children who survive CM. 3 Cerebral malaria is thought to arise from a confluence of inflammatory events, in which infected red blood cells (iRBCs), activated leucocytes and platelets are sequestered on inflamed endothelia due to increased expression of adhesion molecules. 4 It has been suggested that CM results from excessive immune responses that lead to overproduction of pro-inflammatory cytokines, including interferon-c and tumour necrosis factor a.
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The concomitant presence of sequestered parasites and recruited CD8 + T cells in the brain microvasculature reportedly contributed to the development of experimental CM (ECM). 10, 11 Current antimalarial drugs, such as artemether, have been used as therapeutic treatments that also prevent severe malaria in most sub-Saharan African countries. 12 Although artemether suppositories are particularly effective in treating CM, cognitive deficits persist after recovery. 13 Consequently, achieving a parasitological cure is insufficient to ameliorate or protect against the neurological dysfunction often associated with malaria. Anti-tumour necrosis factor therapy is effective for the prevention of ECM in animals, but has shown no effect in human cases. 14, 15 Other treatments, such as L-arginine or nitric oxide administration, appear to be protective in mice and humans. 14, 16, 17 Tacrolimus was first approved for use as an immunosuppressant in liver transplantation. Tacrolimus suppresses the secretion of T helper type 1 (Th1) cell cytokines by peripheral blood mononuclear cells in a dose-dependent manner.
18 Tacrolimus (FK506) binds to the immunophilin FKBP12, forming a new complex. The FKBP12-FK506 complex inhibits calcineurin, resulting in decreased T-lymphocyte signal transduction and interleukin-2 transcription. 19 Tacrolimus exhibits antimalarial activity against cultured P. falciparum, 20 indicating that the drug exhibits both immunosuppressive effects against Th1 cytokines and parasiticidal activity. We therefore hypothesized that tacrolimus could prevent the development of ECM in C57BL/6 mice. Apart from this, the protection of mycophenolate mofetil (MMF), a T-cell and B-cell suppressor, and montelukast sodium, a leukotriene receptor antagonist, were also examined in this model.
Materials and methods
Mice, parasites and the establishment of ECM C57BL/6 (B6) mice were supplied by SLC Laboratories (Fukuoka, Japan) and were housed under barrier conditions at the Animal Centre of the Institute of Tropical Medicine. Mice used in all experiments were female and between 6 and 8 weeks of age. Plasmodium berghei strain ANKA (PbA) was originally obtained from Dr T. Yanagi at the Nekken Bioresource Centre, which is part of the National Bioresource Project network of A-MED Japan at the Institute of Tropical Medicine, Nagasaki University. Before use in experiments, PbA was passaged once through naive BALB/c mice. PbA was selected for its capacity to induce CM in B6 mouse, with neurological signs (ataxia, paralysis, deviation of the head and convulsions) appearing 6-10 days after infection. Samples of each blood stage of the parasite were stored in liquid nitrogen at a concentration of 50% parasitized RBCs in PBS containing 10% glycerol (Wako Pure Chemical Industries, Ltd., Osaka, Japan). The CM was induced by intraperitoneal injection of 10 5 PbA-infected RBCs (pRBCs). Parasitaemia was monitored by examining Giemsa-stained thin blood smears initially from day 1 to day 8 post-infection and every 2 days afterwards. Parasitaemia was expressed as a percentage of at least 1000 RBCs. The day of patency was determined following microscopic examination of 10 000 RBCs. Laboratory and animal practices of the Animal Centre of NEKKEN, Nagasaki University, were adhered to after approval was obtained from the local Ethics Committee for Animal Care and Research. All experiments were conducted in accordance with local Animal Ethics Committee regulations (Ethical Review Committee at the Institute of Tropical Medicine, Nagasaki University).
Treatment with tacrolimus, MMF and montelukast sodium
A tacrolimus suspension was prepared by diluting oral tacrolimus powder (Astellas Pharma Inc., Tokyo, Japan) in 0Á9% sodium chloride at a concentration 0Á2 mg/ml. The suspension was administered directly into the stomach of each B6 mouse through oral gavage (100 ll/mouse or 0Á8 mg/kg once daily from day 2 to day 8 post-infection). Control infected mice (vehicle) were treated with sodium chloride 0Á9% (100 ll/mouse) following the same administration protocol. Uninfected naive mice were also treated with tacrolimus for 6 days. The MMF (CellCept; Roche, Basel, Switzerland) and montelukast sodium (Singulair; MSD, Kenilworth, NJ) were also diluted in 0Á9% sodium chloride and administered at daily oral doses 80 and 0Á4 mg/kg, respectively, from day 0 to day 8 postinfection.
Measurement of plasma IgG subclass
Plasma at a dilution of 1 : 20 000 in 100 ll of coating buffer (pH 9Á6) was used to coat individual wells in polystyrene plates (lot number, 091611; Nunc, Copenhagen, Denmark), which were then kept at 4°overnight. The plates were washed three times with 0Á05% Tween-20/ PBS. Optimum conditions for blocking non-specific binding were achieved by adding 200 ll per well of 0Á1% blocking buffer (0Á1% Tween-20/PBS; pH 7Á2) and incubating the plates for 1 hr at 37°. The plates were then washed three times with PBS containing 0Á05% Tween-20. A total of 100 ll of horseradish peroxidase-conjugated goat anti-mouse IgG1, IgG2a and IgG2b antibodies diluted 1 : 2500 (Santa Cruz Biotechnology, Inc., Dallas, TX) was added to each well and incubated for 1 hr at room temperature, after which the wells were washed three times with 0Á05% Tween-20/PBS. For colour development, 3,3 0 ,5,5 0 -tetramethylbenzidine (stabilized chromate, Invitrogen, Massachusettes, USA) was prepared and used according to the manufacturer's instructions. The reaction was interrupted after 15 min by the addition of 50 ll of 1 M H 2 SO 4 . Optical density was determined at 450 nm using an enzyme immunoassay reader (BioRad, Hercules, CA).
Isolation of brain mononuclear cells
Mice were anaesthetized and perfused through the left ventricle with PBS (without Ca 2+ and Mg 2+ ). Brain was dissected and maintained in RPMI-1640 without phenol red. Tissues were homogenized by using gentleMacs TM Octo Dissociator with Heater (Miltenyi Biotec, Bergisch Gladbach, Germany). The volume of the cell suspensions was completed to 7 ml with RPMI-1640. Three millilitres of Percol was added to the cell suspension to make a final 30% Percol. The 10 ml cell suspension was then slowly layered on top of the 70% Percol and centrifuged for 25 min at 800 g at 18°without brake. Using a transfer pipette, the layer of debris was gently removed from the top of the tube and 2Á0-3Á0 ml of the 70-30% interphase was collected into a clean conical tube containing 6 ml PBS. Cell suspension was centrifuged for 5 min at 800 g at 18°. The pellet was resuspended in 2 ml of PBS, then transferred to a 5-ml polystyrene tube and washed once more using a centrifuge at 3000 g for 3 min at room temperature. Brain mononuclear cells were stained with Turk's solution (Millipore, Billierica, MD) and counted using a haemocytometer.
Flow cytometric analysis
Brain mononuclear cells were collected and stained for cell surface antigens. Brain mononuclear cells were incubated at room temperature for 30 min with fluorochrome-conjugated monoclonal antibodies against surface antigens. The monoclonal antibodies used were anti-CD3-FITC, CD4-phycoerythrin-Cy7, CD8-allophycocyanin antibodies (BD Pharmingen, Franklin Lakes, NJ or eBioscience, San Diego, CA). Flow cytometric analysis was conducted using FACSVERSE systems (BD Biosciences, Franklin Lakes, NJ), and the resulting data were analysed using FLOW JO software (Tree Star, Inc., Ashland OR).
Statistical analysis
Differences between groups of mice in Kaplan-Meier survival were analysed using the log-rank test. The statistical significance of differences in parasitaemia, antibody levels and cell frequencies was analysed using the non-parametric Mann-Whitney U-test. Values for these parameters indicated in the text represent the median and interquartile range of the data. For all statistical tests, P < 0Á05 was considered indicative of significance. Data were analysed using PRISM 5 (Graphpad Software, Inc., La Jolla, CA).
Results and discussion
Tacrolimus treatment prevented the early mortality of PbA-infected mice In a separate series of experiments, B6 mice were intraperitoneally infected with 10 5 PbA-pRBCs and orally administered 0Á02 mg (0Á8 mg/kg) of tacrolimus or 100 ll of sodium chloride solution daily from day 2 to day 8 post-infection. Survival curves clearly showed that 89% of vehicle mice (controls) succumbed to ECM by day 14 post-infection. In contrast, a lower percentage of tacrolimus-treated mice (tac-mice) (31%) died from ECM (Fig. 1a) , indicating that tacrolimus impeded the neuropathological process. Eventually, the surviving mice in both groups developed a high level of parasitaemia and succumbed to severe anaemia between days 28 and 30 post-infection. The parasitaemia profiles for the two groups of mice were similar between days 1 and 6 postinfection (Fig. 1b) . A difference in the development of peripheral Plasmodium infection between the two groups of mice was observed beginning on day 7, with the level of parasitaemia on day 8 significantly lower in tac-mice than in their control littermates (Fig. 1b) . No improvement in survival rate was observed in the montelukasttreated group compared with controls (Fig. 1c) .
Meanwhile, two of three MMF-treated mice (66%) still survived after day 14 and succumbed to malaria earlier than controls (Fig. 1c) , indicating that MMF is not safe for use in murine malaria. MMF is hydrolysed to mycophenolic acid, an active form that inhibits the activity of inosine monophosphate dehydrogenase. This enzyme is in de novo guanine synthesis pathway required for proliferation of T and B cells. Mice treated with MMF also showed lower death from ECM compared with controls (although not significant), but manifested clinically more severe malnutrition, anaemia (pale skin) and died early compared with control and tac-treated mice. Such outcomes probably result from more severe malaria due to the MMF's immunosuppressive effects. The impacts of MMF in the context of Plasmodium infection should be evaluated in a further study.
In the present study, the fatality rate due to ECM was markedly attenuated in tac-mice. Tacrolimus has been approved for use in organ transplant patients and for the treatment of some human autoimmune diseases and is therefore a candidate for adjunctive therapy for human CM. The capacity for tacrolimus to inhibit the malaria parasite was observed during the period in which ECM occurs (days 7-8). This finding was consistent with the results of previous in vitro studies 20, 21 showing that tacrolimus inhibits P. falciparum proliferation by interfering with the binding domain of P. falciparum FKBP35. Previous studies have shown that reducing the Plasmodium burden prevents the development of neuropathology. 10, 22, 23 Low parasite burden is related to protection from ECM, as shown by mouse models showing a reduction in the sequestration of iRBCs and infiltrating CD8 + T cells. 10, 11 In humans, there is a weak correlation between high parasitaemia levels and CM. 4 However, sequestration does occur during P. falciparum malaria, and the adherence of iRBCs probably induces signals within endothelial cells after binding to cell adhesion molecules, eliciting a disruption of tight endothelial junctions and, possibly, increased cell adhesion molecule expression. 24 Hypothetically, CM occurs when the number of parasites sequestered or accumulated in the brain reaches a certain level that results in sequential destruction of the blood-brain barrier following the sequestration of iRBCs and immune cells among brain endothelial cells. Therefore, a low parasitaemia level could reduce the sequestration of iRBCs on cerebral vessels. Nevertheless, the difference in parasitaemia was only observed in treated mice from day 8 post-infection when only 20% of mice died compared with 40% death of non-treated controls, indicating that lowering parasitaemia is probably one of the protective effects of tacrolimus. Suppression of T cells in treated mice could be another mechanism of protection from ECM, especially within the first week of infection. A previous study also showed that tacrolimus attenuates the severity of brain microgliosis, 25 which has been identified as a factor in the pathogenesis of ECM.
Hence, tacrolimus may prevent ECM through a direct effect on the brain.
Tacrolimus enhanced the production of IgG2a in infected and naive mice
Apart from the reported effect of tacrolimus on inhibition of T-cell proliferation, in the present study, the humoral immune response was examined in infected and naive mice treated with tacrolimus. As the balance between Th1 and Th2 cytokines contributed the development of ECM, Th2-related IgG1 and Th1-related IgG2a, IgG2b were measured. Unexpectedly, plasma IgG2a levels on day 8 (but not day 5) post-infection were higher in tac-mice than in untreated infected controls, although this difference was not significant (P = 0Á06) (Fig. 2a,b) . To confirm the impact of tacrolimus on IgG-subclass production, naive (non-infected) mice were also treated with tacrolimus. The level of IgG2a post-treatment (day 7 of administration) in naive mice was also significantly enhanced compared with the pre-treatment level (P < 0Á05) (Fig. 2c) . In contrast, no differences in the levels of plasma IgG1 and IgG2b were observed between the two groups of infected mice (Fig. 2a,b) or between pre-and post-treatment in naive mice (Fig. 2c) .
Research has suggested that tacrolimus inhibits antibody formation in transplant patients. 26 In the present study, tacrolimus at a dose of 0Á8 mg/kg did not suppress antibody production, but did enhance plasma Th1-related IgG2a levels in both malaria-infected and naive mice. The relatively higher dose of tacrolimus used in the present study (0Á8 mg/kg versus 0Á1-0Á2 mg/kg) influenced the humoral immune response in mice. The perturbation is that tacrolimus suppresses T-cell proliferation, activation but enhances the production of Th1-induced IgG2a. It is hypothesized that a high dose of tacrolimus could inhibit the accumulation and activation of local T cells in the brain of ECM mice but not systemic T cells. This mechanism should be elucidated in further studies. Antibodies block parasite invasion of erythrocytes and enhance the opsonization of parasites for phagocytosis by macrophages. 27 Consequently, the high production of IgG2a should be positively correlated with the low parasitaemia in treated mice. The unexpected present observations of low parasitaemia levels and high antibody production in mice treated with tacrolimus are encouraging with respect to further therapeutic developments.
Tacrolimus attenuated the sequestration of pathogenic CD8 + T cells in brain
It was clearly shown that CD8 + T-cell sequestration in brain is required for development of experimental cerebral malaria. 10 Therefore, we further sought the effects of tacrolimus on brain infiltrating T cells during malaria infection. As expected, the number of mononuclear cells in brain on day 7 was significantly lower in tac-mice than in their counterparts (4Á8 9 10 4 versus 7Á4 9 10 4 , respectively) (Fig. 3b) . It was found that the percentage of brain sequestered T, CD4
+ and CD8 + T cells on day 7 was comparable between two groups of mice (13Á9% versus 16Á1%, 1Á8% versus 1Á4% and 10Á9% versus 12Á9%, respectively) (Fig. 3c) . Nonetheless, the number of CD8 + T cells infiltrating to the brain on day 7 was reduced in tac-mice compared with counterparts (5677 versus 10 626; respectively) whereas these mice showed no difference in the number of sequestered CD4 + T cells (867 versus 1166, respectively) (Fig. 3d) . Apart from this, the ratio of CD8 + /CD4 + T cells in brain was lower in tacmice than control littermates, though not significantly ( Fig. 3e , P = 0Á06). Hence, tacrolimus probably had a protective effect against ECM by attenuating the cerebral infiltration of pathogenic CD8 + T cells. This finding is in agreement with the previous studies showing the reduction of tacrolimus-induced CD8 + T-cell number in bone and graft-versus-host diseases. 28, 29 Cytoadherence of iRBCs on brain endothelium causing the microvascular obstruction is a hallmark of human CM whereas the sequestration of leucocytes, especially CD8 + T cells in the brain vessels, is more prominent than that of parasitized erythrocytes in PbA ECM. 30 Hence, the reduced mortality due to ECM in tacrolimus-treated PbA-infected mice observed in the present study was probably the consequence of a decrease of brain infiltrating CD8 + T cells and to a lesser extent, low parasitaemia levels. The pathophysiology of human CM and PbA ECM are not completely identical and the effect of tacrolimus on cytoadherence of iRBCs on brain endothelium has not been elucidated. It is still consequently questionable whether the further study of tacrolimus administered after the onset of PbA ECM is possible when applied to treating human CM. In addition, our other current data showed that tacrolimus did not inhibit the number of splenic T, dendritic and natural killer cells. This finding needs to be confirmed by further experiments in malaria or other infections. Taken together, in the present murine malaria study, tacrolimus was used safely. Hence, the combination therapy with tacrolimus and antimalarial agents should be further studied for the prevention and treatment of human CM.
